Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Dapagliflozin has been shown to lower clinic systolic and diastolic blood pressure in
patients with type 2 diabetes mellitus. The exact mechanism(s) by which dapagliflozin lowers
clinic SBP is unknown. The primary objective of the study is to determine the effect of
dapagliflozin , 10 mg daily, on parameters of arterial stiffness: aPWV, augmentation index
(AI), 24-hour blood pressure patterns, SBP, and pulse pressure. Urinary sodium excretion, and
Intravascular volume status will be recorded. The study will involve 21 subjects for a
duration of 16 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Gulf Regional Research & Educational Services, LLC